{
    "Trade/Device Name(s)": [
        "V8 Nexus Hemoglobin UltraScreen",
        "V8 AFSA2 Hemo Control"
    ],
    "Submitter Information": "Helena Laboratories, Corp.",
    "510(k) Number": "K192931",
    "Predicate Device Reference 510(k) Number(s)": [
        "K112491"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GKA",
        "JBD"
    ],
    "Summary Letter Date": "April 19, 2022",
    "Summary Letter Received Date": "October 17, 2019",
    "Submission Date": "October 16, 2019",
    "Regulation Number(s)": [
        "21 CFR 864.7415",
        "21 CFR 864.7440"
    ],
    "Regulation Name(s)": [
        "Abnormal Hemoglobin Assay"
    ],
    "Analyte Class(es)": [
        "hematology"
    ],
    "Analyte(s)": [
        "Hemoglobin A",
        "Hemoglobin A2",
        "Hemoglobin F",
        "Hemoglobin S",
        "Hemoglobin C"
    ],
    "Specimen Type(s)": [
        "Hemolysate of venous whole blood"
    ],
    "Specimen Container(s)": [
        "K2EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "V8 Instrument",
        "V8 Capillary Electrophoresis (CE) system"
    ],
    "Method(s)/Technology(ies)": [
        "Capillary zone electrophoresis"
    ],
    "Methodologies": [
        "Protein separation by electrophoretic mobility",
        "Electropherogram analysis"
    ],
    "Submission Type(s)": [
        "Assay",
        "Analyzer",
        "Control",
        "Reagent",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for Helena V8 Nexus Hemoglobin UltraScreen and AFSA2 Hemo Control for quantitative and qualitative hemoglobin variant analysis by capillary zone electrophoresis",
    "Indications for Use Summary": "Intended for separation and quantitation of normal hemoglobins (A, A2, F) and detection of variants (S, C) in human whole blood (2+ years old) using V8 instrument with K2EDTA hemolysate; AFSA2 Hemo Control is used as a control for UltraScreen on the V8 CE system",
    "fda_folder": "Hematology"
}